HK Stock Market Move | HEARTCARE-B(06609) surges by over 13%, achieving a substantial turnaround from loss to profit for the year. The company plans to apply for listing on the A-share Science and Technology Innovation Board.

HEARTCARE-B (06609) rose more than 13% again, with a cumulative increase of over 40% after the performance announcement. As of the release, it rose by 8.24% to 59.1 Hong Kong dollars, with a trading volume of 134.367 million Hong Kong dollars. On the news front, XINWEI Medical recently released its annual performance, with the company achieving a revenue of 408 million yuan for the full year, a year-on-year increase of 46.9%. At the same time, the company's current gross profit margin has remained stable at over 70%, and net profit reached 83.34 million yuan, achieving a significant turnaround from loss to profit year-on-year, marking the company's layout in the field of neurointervention entering a period of harvest. It is worth noting that the company plans to submit an application for listing on the A-share Science and Technology Innovation Board in 2026. The company's management proposed multiple development goals at the performance meeting: to maintain an annualized revenue growth of no less than 35% in the next three years, to strive to achieve the top market share for domestically produced neurointervention brands by 2028; in terms of overseas income, it is expected to contribute more than 10% by 2028, exceeding 100 million yuan in scale; on the profit side, the company is committed to achieving a net profit margin of about 20%, with the gross profit margin expected to remain stable in the 68%-70% range, ensuring profitability stability through refined expense management and economies of scale.